A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)-Reference-Cited by-同舟云学术

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

Published:2024-02-08 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Guerra Andrea¹,Costantino Claudio²,Martinon-Torres Federico³⁴⁵,Westerholt Soeren⁶,Lambeth Courtney⁷,Chen Ziqiang⁷,Lumley Jessie⁷,Marcek Tomas⁸,Johnson David⁹,Wilck Marissa⁷^ORCID

Affiliation:

1. Research, MSD (UK) Limited, London, UK

2. Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Excellence Specialties, University of Palermo, Palermo, Italy

3. Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

4. GENVIP Research Group (www.genvip.eu), Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain

5. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

6. Pediatrics, Praxis für Kinder- und Jugendmedizin, Wolfsburg, Germany

7. Research, Merck & Co., Inc., Rahway, NJ, USA

8. Vaccine, MCM Vaccine B.V, Leiden, Netherlands

9. Vaccine, Sanofi Vaccines, Swiftwater, PA, USA

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2310900

Reference33 articles.

1. Hexavalent vaccines for immunization in paediatric age

2. New perspectives for hexavalent vaccines

3. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children

4. Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP-T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants

5. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11–12 months